Keros Therapeutics (KROS) Tops Q1 EPS by 481c

Keros Therapeutics (NASDAQ: KROS) reported Q1 EPS of $3.62, $4.81 better than the analyst estimate of ($1.19). Revenue for the quarter came in at $211.25 million versus the consensus estimate of $1.26 million.

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Mosaic sets pricing for tender offers on up to $1.4B in debt
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery